Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + triamcinolone (Shahid Beheshti University of Medical Sciences)
- Development stage
- Phase 4
- Lead developer
- Shahid Beheshti University of Medical Sciences
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Ophthalmic
01
Overview
bevacizumab + triamcinolone is a combination therapy investigated by Shahid Beheshti University of Medical Sciences for the treatment of macular edema and visual impairment associated with central retinal vein occlusion (CRVO). Bevacizumab is a recombinant humanized monoclonal antibody that binds to and neutralizes vascular endothelial growth factor (VEGF), a key mediator of angiogenesis and vascular permeability. Triamcinolone acetonide is a synthetic corticosteroid that provides potent anti-inflammatory effects and stabilizes the blood-retinal barrier by inhibiting inflammatory cytokines and reducing capillary leakage. The combination is administered via intravitreal injection to provide a synergistic approach, targeting both the VEGF-driven and inflammatory pathways that contribute to retinal edema and vision loss in CRVO patients.
- Other names
- bevacizumab plus triamcinoloneintravitreal bevacizumab and triamcinoloneAvastin and triamcinolone
02
Targets
GR (Glucocorticoid receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on bevacizumab + triamcinolone (Shahid Beheshti University of Medical Sciences).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + triamcinolone (Shahid Beheshti University of Medical Sciences).